Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells
Abstract
Replication-competent oncolytic viruses are being developed for human cancer therapy. We previously reported that an attenuated adenovirus OBP-301 (Telomelysin), in which the human telomerase reverse transcriptase promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site, could replicate in and causes selective lysis of human cancer cells. Infection efficiency in target cancer cells is the most important factor that predicts the antitumor effects of OBP-301. The objectives of this study are to examine the effects of the histone deacetylase inhibitor FR901228 on the level of coxsackie and adenovirus receptor (CAR) expression and OBP-301-mediated oncolysis in human non-small cell lung cancer cell lines. Flow cytometric analysis revealed up-regulated CAR expression in A549 and H460 cells following treatment with 1 ng/ml of FR901228, which was associated with increased infection efficiency as confirmed by replication-deficient beta-galactosidase-expressing adenovirus vector. In contrast, neither CAR expression nor infection efficiency was affected by FR901228 in H1299 cells. To visualize and quantify viral replication in the presence of FR901228, we used OBP-401 (Telomelysin-GFP) that expresses the green fluorescent protein (GFP) reporter gene under the control of the cytomegalovirus promoter in the E3 region. Fluorescence microscopy and flow cytometry showed that FR901228 increased GFP expression in A549 and H460 cells following OBP-401 infection in a dose-dependent manner, but this effect did not occur in H1299 cells. In addition, OBP-301 and FR901228 demonstrated a synergistic antitumor effect in A549 cells in vitro, as confirmed by isobologram analysis. Our data indicate that FR901228 preferentially increases adenovirus infectivity via up-regulation of CAR expression, leading to a profound oncolytic effect, which may have a significant impact on the outcome of adenovirus-based oncolytic virotherapy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Cites
Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5
Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt‐Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., & Finberg, R. W. (1997) · Science · doi:10.1126/science.275.5304.1320 · Cited by 3,102 · see citing works
Cooperation between Complexes that Regulate Chromatin Structure and Transcription
Narlikar, G. J., Fan, H.-Y., & Kingston, R. E. (2002) · Cell · doi:10.1016/s0092-8674(02)00654-2 · Cited by 1,486 · see citing works
Tomko, R. P., Xu, R., & Philipson, L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3352 · Cited by 1,200 · see citing works
Heise, C. C., Sampson-Johannes, A., Williams, A., McCormick, F. P., Hoff, D. D. V., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 941 · see citing works
The polypeptides of adenovirus
Maizel, J. V., WHITE, D. O., & Scharff, M. D. (1968) · Virology · doi:10.1016/0042-6822(68)90121-9 · Cited by 883 · see citing works
(2002) · PubMed · Cited by 732 · see citing works
Ueda, H., Nakajima, H., Hori, Y., Fujita, T., Nishimura, M., Goto, T., & OKUHARA, M. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.301 · Cited by 493 · see citing works
FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor
Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M., & Horinouchi, S. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4027 · Cited by 484 · see citing works
Nemunaitis, J. J., Khuri, F. R., Ganly, I., Arseneau, J. C., Posner, M. R., Vokes, E. E., Kuhn, J. A., McCarty, T. M., Landers, S., Blackburn, A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.289 · Cited by 470 · see citing works
A SIMPLE AND EFFICIENT METHOD FOR PURIFICATION OF INFECTIOUS RECOMBINANT ADENOVIRUS
Kanegae, Y., Makimura, M., & Saito, I. (1994) · Japanese Journal of Medical Science and Biology · doi:10.7883/yoken1952.47.157 · Cited by 444 · see citing works
Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2004-05-1693 · Cited by 400 · see citing works
DeWeese, T. L., der Poel, H. V., Li, S., et al. (2001) · PubMed · Cited by 384 · see citing works
Reid, T. R., Galanis, E., Abbruzzese, J. L., Sze, D., Wein, L. M., Andrews, J., Randlev, B., Heise, C. C., Uprichard, M. J., Hatfield, M. J., et al. (2002) · PubMed · Cited by 309 · see citing works
Chiocca, E. A. (2002) · Nature reviews. Cancer · doi:10.1038/nrc948 · Cited by 306 · see citing works
Telomerase-Specific Replication-Selective Virotherapy for Human Cancer
Kawashima, T., Kagawa, S., Kobayashi, N., Shirakiya, Y., Umeoka, T., Teraishi, F., Taki, M., Kyo, S., Tanaka, N., & Fujiwara, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1075-3 · Cited by 262 · see citing works
Self-citationA phase I trial of Depsipeptide (FR901228) in patients with advanced cancer
Marshall, J. L., Rizvi, N. A., Kauh, J. S. W., et al. (2002) · Journal of Experimental Therapeutics and Oncology · doi:10.1046/j.1359-4117.2002.01039.x · Cited by 205 · see citing works
Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
Yu, D., Chen, Y., Dilley, J., et al. (2001) · PubMed · Cited by 172 · see citing works
Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer
Hamid, O., Varterasian, M. L., Wadler, S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.114 · Cited by 143 · see citing works
Oncolytic biotherapy: a novel therapeutic platform
Hawkins, L. K., Lemoine, N. R., & Kirn, D. H. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00618-0 · Cited by 131 · see citing works
Hemminki, A., Kanerva, A., Liu, B., et al. (2003) · PubMed · Cited by 101 · see citing works
Anders, M., Christian, C., McMahon, M., et al. (2003) · PubMed · Cited by 98 · see citing works
Kitazono, M., Goldsmith, M. E., Aikou, T., et al. (2001) · PubMed · Cited by 93 · see citing works
Nishizaki, M., Meyn, R. E., Levy, L. B., Atkinson, E. N., White, R. A., Roth, J. A., & Ji, L. (2001) · PubMed · Cited by 87 · see citing works
Self-citationTaki, M., Kagawa, S., Nishizaki, M., Mizuguchi, H., Hayakawa, T., Kyo, S., Nagai, K., Urata, Y., Tanaka, N., & Fujiwara, T. (2005) · Oncogene · doi:10.1038/sj.onc.1208460 · Cited by 86 · see citing works
Self-citationHassan, M., van der Meulen‐Muileman, I. H., Abbas, S., & Kruyt, F. A. E. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12243-12251.2004 · Cited by 85 · see citing works
Umeoka, T., Kawashima, T., Kagawa, S., Teraishi, F., Taki, M., Nishizaki, M., Kyo, S., Nagai, K., Urata, Y., Tanaka, N., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1335 · Cited by 72 · see citing works
Self-citationZhang, J., Ramesh, N., Chen, Y., Li, Y., Dilley, J., Working, P. K., & Yu, D. (2002) · PubMed · Cited by 68 · see citing works
Pong, R.-C., Lai, Y., Chen, H., et al. (2003) · PubMed · Cited by 67 · see citing works
Xiao, J. J., Huang, Y. S., Dai, Z., et al. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.083956 · Cited by 66 · see citing works
Goldsmith, M. E., Kitazono, M., Fok, P. T., et al. (2003) · PubMed · Cited by 54 · see citing works
Yamano, T., Ura, K., Morishita, R., Nakajima, H., Monden, M., & Kaneda, Y. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0074 · Cited by 51 · see citing works
Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors
Borovjagin, A. V., Krendelchtchikov, A., Ramesh, N., et al. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700806 · Cited by 45 · see citing works
Mizuguchi, H., & Hayakawa, T. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700440 · Cited by 44 · see citing works
Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells
Kitazono, M., Rao, V. K., Robey, R. W., et al. (2002) · Blood · doi:10.1182/blood.v99.6.2248 · Cited by 41 · see citing works
Tango, Y., Taki, M., Shirakiya, Y., Ohtani, S., Tokunaga, N., Tsunemitsu, Y., Kagawa, S., Tani, T., Tanaka, N., & Fujiwara, T. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03232.x · Cited by 18 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus
Kishimoto, H., Kojima, T., Watanabe, Y., Kagawa, S., Fujiwara, T., Uno, F., Teraishi, F., Kyo, S., Mizuguchi, H., Hashimoto, Y., et al. (2006) · Nature Medicine · doi:10.1038/nm1404 · Cited by 179 · see citing works
Self-citation
- Authors
- Watanabe, T., Hioki, M., Fujiwara, T., Nishizaki, M., Kagawa, S., Taki, M., Kishimoto, H., Endo, Y., Urata, Y., Tanaka, N., & Fujiwara, T.
- Affiliations
- Okayama University (JP)
- Oncolys BioPharma (Japan) (JP)
- Corresponding author
- Fujiwara, Toshiyoshi
- Venue
- Experimental Cell Research
- Publisher
- Elsevier BV
- Published
- 2006-02
- Volume
- 312
- Issue
- 3
- Pages
- 256-265
- ISSN
- 0014-4827 (ISSN-L)
- OpenAlex
- W2064951429
- Cited by
- 88
- References
- 35
- Citations by year
- 2026: 2 · 2025: 2 · 2023: 5 · 2022: 2 · 2021: 1 · 2020: 2 · 2018: 5 · 2017: 3 · 2016: 3 · 2015: 1 · 2014: 4 · 2013: 7 · 2012: 7
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Experimental Cell Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- histone deacetylase inhibitors, OBP-301, oncolytic adenovirus, telomerase reverse transcriptase promoter, coxsackievirus and adenovirus receptor, CAR expression, non-small cell lung cancer, oncolytic virotherapy, synergistic antitumor effect, telomerase, A549 cells, H460 cells, H1299 cells
- MeSH terms
- Adenoviridae, Adenoviridae Infections, Antibiotics, Antineoplastic, Carcinoma, Non-Small-Cell Lung, Cell Cycle, Cell Survival, DNA-Binding Proteins, Enzyme Inhibitors, Flow Cytometry, Humans, Lung Neoplasms, Promoter Regions, Genetic, Receptors, Virus, Virus Replication, Genetic Therapy, Adenovirus E1 Proteins, Telomerase, Cell Line, Tumor, Depsipeptides, Green Fluorescent Proteins, Oncolytic Viruses, Histone Deacetylase Inhibitors, Coxsackie and Adenovirus Receptor-Like Membrane Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
